Antiretroviral Therapy (ART): Drug Classes, Regimens and Monitoring
On this page
01
Overview
02
Drug classes and the HIV life cycle
Each ART class blocks a different step of HIV replication (figure 1). Combination ART (cART) — at least three drugs from at least two classes — suppresses viral replication to undetectable levels, allows immune recovery, and makes onward transmission effectively zero (U=U: undetectable = untransmittable).

Scroll the table sideways on a smaller screen.
| Class | Target / mechanism | Agents | Resistance barrier | Role |
|---|---|---|---|---|
| Nucleoside reverse transcriptase inhibitors (NRTIs) | Incorporated into viral DNA by reverse transcriptase, then terminate the chain (compete with natural nucleotides) | Tenofovir (TDF/TAF), lamivudine (3TC), emtricitabine (FTC), zidovudine (AZT), abacavir (ABC) | Low–moderate | Two NRTIs form the backbone of every regimen |
| Non-nucleoside RT inhibitors (NNRTIs) | Allosteric binding to reverse transcriptase — non-competitive inhibition | Efavirenz (EFV), nevirapine (NVP), rilpivirine (RPV), doravirine | Low (single mutation, e.g. K103N, confers cross-resistance) | Formerly first-line third drug; falling out of favour with DTG scale-up |
| Integrase strand transfer inhibitors (INSTIs) | Block integrase — viral DNA cannot insert into the host genome | Dolutegravir (DTG), bictegravir, raltegravir, elvitegravir | High (DTG) | Preferred third drug — Uganda and WHO first line |
| Protease inhibitors (PIs) | Block viral protease — immature, non-infectious virions result | Lopinavir/r (LPV/r), atazanavir/r (ATV/r), darunavir/r (DRV/r) | High (need multiple mutations; ritonavir boosting) | Second-line anchor; special situations (young children) |
| Entry / fusion inhibitors | Block CCR5 co-receptor (maraviroc) or gp41 fusion (enfuvirtide) | Maraviroc, enfuvirtide | — | Third-line/specialist only |
03
NRTIs in detail
Scroll the table sideways on a smaller screen.
| Drug | Adult dose | Paediatric dose | Main uses | Adverse effects | Contraindications / interactions | Counselling |
|---|---|---|---|---|---|---|
| Tenofovir disoproxil fumarate (TDF) | 300 mg once daily (fixed with 3TC + DTG as TLD) | As FDC by weight band (child dosing per national chart) | First-line backbone NRTI; also hepatitis B monotherapy | Renal tubular toxicity (check creatinine/eGFR), reduced bone density, nausea; rare Fanconi syndrome; lactic acidosis/hepatic steatosis (class effect, rare) | Avoid if eGFR <60 (use ABC/AZT per guidelines); nephrotoxic co-drugs (aminoglycosides, amphotericin, tenofovir + boosted PIs ↑ levels) | Take with or without food; report muscle weakness, bone pain, passing less urine; do not stop if also treating HBV (flare risk) |
| Lamivudine (3TC) | 300 mg once daily | Weight-band | Backbone NRTI in virtually every regimen; also anti-HBV | Very well tolerated; headache, nausea; pancreatitis (rare, children); lactic acidosis (rare) | None significant | Never stop alone if HBV co-infected (flare) |
| Zidovudine (AZT) | 300 mg 12-hourly | Weight-band | Alternative backbone (renal impairment); second-line anchor partner | Macrocytic anaemia/neutropenia (monitor FBC at 4–6 wks), nausea, headache, myopathy, lipoatrophy, lactic acidosis, neonatal use safe | Avoid if baseline Hb low; stavudine (d4T) withdrawn — same class toxicity (avoid re-challenge) | Report pallor, breathlessness, unusual tiredness (anaemia) |
| Abacavir (ABC) | 600 mg once daily | Weight-band | Backbone alternative (e.g. TDF contraindicated, adolescents <35 kg) | Hypersensitivity reaction (HSR) — fever, rash, GI, respiratory; can be fatal on re-challenge; lactic acidosis (rare) | Do NOT re-challenge after HSR (always document!); test HLA-B*57:01 where available | Report fever/rash immediately; carry the warning card |
04
NNRTIs in detail
Scroll the table sideways on a smaller screen.
| Drug | Adult dose | Paediatric dose | Main uses | Adverse effects | Contraindications / interactions | Counselling |
|---|---|---|---|---|---|---|
| Efavirenz (EFV) | 600 mg once daily at night | Weight-band (200–400 mg by weight); <3 yr avoid | Former first-line third drug; still widely used; TB co-treatment compatible (600 mg maintained) | CNS effects — vivid dreams, dizziness, poor concentration (weeks 1–2, usually settle); rash; raised lipids; possible neural-tube-defect signal in early pregnancy (low absolute risk) | Psychiatric illness (depression/suicidality — caution); CYP3A4 inducer (↑ metabolism of many drugs, ↓ contraceptive efficacy, ↓ voriconazole, ↓ some anticoagulants) | Take at bedtime; avoid driving until settled; do not stop for vivid dreams alone; use reliable contraception |
| Nevirapine (NVP) | 200 mg once daily ×14 d, then 200 mg 12-hourly | Weight-band | Alternative first-line; PMTCT regimens; children | Rash → SJS/TEN (lead-in dosing halves risk; stop at rash), hepatotoxicity (monitor LFTs; higher in women with CD4 >250/men >400) | Hepatic impairment; never start if CD4 above thresholds in adults; enzyme inducer | Report any rash at once; take lead-in dose exactly |
| Rilpivirine (RPV) | 25 mg once daily with food | >12 y only | Alternative (not with baseline viral load >100,000; not with TB on rifampicin) | Rash, depression, insomnia | Gastric pH — avoid PPIs, separate antacids; food requirement (with a meal) | Always take with a meal |
05
Integrase inhibitors (INSTIs)
Scroll the table sideways on a smaller screen.
| Item | Details |
|---|---|
| Dose | 50 mg once daily (TLD fixed-dose combination); 50 mg twice daily when co-treated with rifampicin (and for some INSTI resistance); separate from polyvalent cations (antacids, calcium, iron — take 2 h apart) |
| Mechanism | Binds integrase active site → viral DNA cannot integrate into host genome; high genetic barrier to resistance (requires multiple mutations) |
| Adverse effects | Generally very well tolerated; insomnia, headache; weight gain (notable metabolic signal); rare hypersensitivity with liver injury |
| Interactions | Rifampicin → double the dose; polyvalent cations chelate (separate dosing); metformin levels ↑ (monitor) |
| Special points | Safe in pregnancy/breastfeeding (preferred by Uganda 2020+ guidance); rapid viral suppression; long half-life forgiving of occasional missed doses |
06
Protease inhibitors (PIs)
Scroll the table sideways on a smaller screen.
| Drug | Dose | Uses | Adverse effects | Interactions / cautions |
|---|---|---|---|---|
| Lopinavir/ritonavir (LPV/r) | 400/100 mg 12-hourly (tablets); paediatric syrup weight-band | Children <3 y (with ABC+3TC); second line | GI upset (very common), lipid elevation, insulin resistance/diabetes, fat redistribution, QT prolongation | Ritonavir = potent CYP3A4 inhibitor → huge interaction list (statins contraindicated except pravastatin; ↑ rifabutin; many others); avoid with rifampicin |
| Atazanavir/ritonavir (ATV/r) | 300/100 mg once daily | Second line (adults) | Indirect hyperbilirubinaemia (harmless jaundice), nephrolithiasis, PR prolongation, rash | As LPV/r; requires gastric acid (separate antacids/H2 blockers); avoid rifampicin |
| Darunavir/ritonavir (DRV/r) | 800/100 mg once daily | Third line / salvage | Rash (SJS rare), hepatotoxicity, lipids | Resistance testing needed; specialist use |
PIs are always "boosted" with a small dose of ritonavir (or cobicistat) that inhibits CYP3A4, raising and prolonging the PI level — this is a pharmacokinetic enhancer, not an antiviral.
07
Uganda regimens and special populations
Scroll the table sideways on a smaller screen.
| Population | First line | Alternatives / second line |
|---|---|---|
| Adults & adolescents ≥10 y | TDF + 3TC + DTG (TLD) once daily | TDF+3TC+EFV; ABC+3TC+DTG if TDF contraindicated (eGFR <60, <35 kg). Second line: AZT+3TC + ATV/r (or LPV/r), guided by viral load |
| Children 3–<10 y | ABC + 3TC + DTG (per national optimisation) | ABC+3TC+EFV; second line PI-based |
| Children <3 y | ABC + 3TC + LPV/r (high resistance barrier; NVP failed too often) | ABC+3TC+RAL in some settings |
| Pregnancy / breastfeeding | TLD (DTG preferred; EFV alternative) | As adults; do not delay ART |
| TB co-treatment | TLD with DTG 50 mg twice daily during rifampicin (EFV needs no adjustment) | Avoid PI + rifampicin combination |
- Baseline before ART: HIV confirmation, CD4 (severity/OI risk), viral load, HBsAg (HBV changes regimen), creatinine/eGFR (TDF), FBC (if AZT), TB screening (symptom screen ± Xpert), pregnancy test, STI screen.
- Monitoring: viral load at 6 and 12 months then annually (target <1000 copies/mL = suppressed); adherence counselling at every visit; clinical staging.
08
PEP, PrEP and PMTCT
- Post-exposure prophylaxis (PEP): after occupational or sexual exposure, start TDF+3TC+DTG (or TLD) within 72 hours (ideally <2 h), for 28 days; baseline HIV test, follow-up testing at 6 weeks, 3 months (and 6 months per guidelines). Do not delay the first dose for testing.
- Pre-exposure prophylaxis (PrEP): TDF/FTC (or TDF/3TC) daily for HIV-negative people at substantial risk — serodiscordant couples, key populations; requires regular HIV testing (drug resistance if given during undiagnosed acute HIV).
- PMTCT: ART for all HIV-positive pregnant/breastfeeding women (lifelong), infant prophylaxis (e.g., NVP or AZT syrup per national protocol), safe infant feeding counselling, and early infant diagnosis at 6 weeks (DNA PCR).
- U=U: sustained viral suppression means no sexual transmission — a powerful adherence motivator.
09
Adverse effects, interactions and adherence
Scroll the table sideways on a smaller screen.
| Partner drug | ARV affected | Effect / action |
|---|---|---|
| Rifampicin (TB) | DTG | ↓ DTG levels → DTG 50 mg twice daily |
| Rifampicin | PIs (LPV/r, ATV/r, DRV/r), RPV, most NNRTIs | Marked ↓ levels → avoid PI combinations; EFV 600 mg maintained; specialist input |
| Ritonavir/cobicistat (boosters) | Statins (simvastatin/lovastatin), rifabutin, some anticoagulants, sedatives | ↑ partner levels → simvastatin contraindicated; reduce rifabutin dose |
| Polyvalent cations (antacids, Ca, Fe, Mg) | DTG (and RPV) | Chelation → separate by 2 h (DTG before or after) |
| Carbamazepine, phenytoin, phenobarbital | DTG, PIs, many ARVs | Enzyme induction → avoid or adjust with specialist advice |
| Oral contraceptives | EFV, rifampicin-containing TB therapy | ↓ contraceptive levels → add condoms or switch method |
10
Clinical scenarios
Scenario 1 — Starting ART at the HIV clinic
A 29-year-old woman, newly diagnosed (CD4 320, viral load 45,000, HBsAg negative, eGFR normal, not pregnant), is started on TLD once daily the same day (test and treat). You counsel: take the same time daily; if she starts TB treatment she will need the twice-daily dolutegravir adjustment; separate from iron tablets and antacids; expect viral suppression by 6 months; and that with sustained suppression she cannot transmit HIV sexually. Follow-up: viral load at 6 months — detectable VL with good adherence prompts enhanced support first, then resistance testing if persistent.
Scenario 2 — Needle-stick injury at the ward
A house officer sustains a deep needle-stick from an HIV-positive patient (viral load unknown) during a procedure. You wash the wound, don't squeeze it, and start PEP (TLD) within 2 hours — 28 days, after baseline HIV/HBV/HCV and pregnancy tests (she is not pregnant). You counsel on side effects, schedule follow-up tests, and remind her the regimen must be completed even if the source's tests return negative-ish patterns. First dose never waits for paperwork.
Scenario 3 — Rash on nevirapine
A 41-year-old man, 10 days into TDF+3TC+NVP (lead-in completed), develops a widespread maculopapular rash with fever. You stop all ARVs immediately (NVP SJS/TEN risk) — and counsel that he must never take NVP again. You switch his regimen per guidelines once the rash resolves (e.g., to TLD if no contraindication) with close early review. Document the reaction in his booklet and the clinic register.
11
Key points
12
References
- Uganda Consolidated Guidelines for Prevention and Treatment of HIV and AIDS (MoH, 2020 revision and updates) (Library reference.)
- WHO Consolidated Guidelines on the Use of Antiretroviral Drugs (Library reference.)
- WHO HIV/AIDS fact sheets: ART coverage and U=U statements (Library reference.)
- Katzung's Basic & Clinical Pharmacology — antiviral agents chapter (Library reference.)
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (Library reference.)
13
Further reading
For deeper study, compare this lesson with current guidance and standard references from recognised medical and pharmaceutical organisations.
- WHO: HIV/AIDS
- NIH AIDSinfo — antiretroviral drug database and interactions
- Uganda MoH Knowledge Management Portal (HIV guidelines)
- DCM Year One Semester Two curriculum
For education only. ART must be prescribed per the current Uganda Consolidated HIV Guidelines and national ART programme — verify regimens, interactions and monitoring schedules in practice.